PEGylated IL-2 With Controllable Binding Sites for Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing IL-2 therapies face challenges such as low efficacy, short half-life, significant side effects, and a narrow dosage window due to its dual functions and high affinity for regulatory T cells, limiting their clinical use in cancer treatment.
Innovation Solution
A method for preparing PEGylated IL-2 by selectively adding 1-2 PEG chains to IL-2, allowing it to bind preferentially to IL-2Rβγ receptors, thereby enhancing its therapeutic efficacy and reducing side effects through controlled binding sites.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high dose of IL-2 is used to activate killer immune cells, then anti-tumor efficacy is improved, but side effects such as severe hypotension and vascular leak syndrome increase significantly
Solution Approach 1:
The patent applies local quality by selectively modifying specific amino acid residues (such as Lys17, Lys28, Lys96) of the IL-2 molecule with PEG chains. This localized modification approach allows the drug to maintain high affinity for IL-2Rβγ receptors on killer immune cells while reducing non-specific binding to regulatory T cells, thereby improving therapeutic efficacy while minimizing side effects associated with high-dose administration.
Solution Approach 2:
The patent changes the physicochemical parameters of the IL-2 molecule by conjugating PEG chains at controlled positions and densities. This modification alters the pharmacokinetic properties including half-life extension and reduces immunogenicity, allowing the drug to achieve sustained therapeutic levels without requiring high doses that cause severe side effects.
2Adaptability or versatility
If IL-2 is modified to reduce affinity for regulatory T cells, then selectivity for killer immune cells is improved, but binding efficiency may be reduced
Solution Approach 1:
The patent modifies specific local regions of the IL-2 molecule (particularly basic amino acid residues at positions 17, 28, and 96) with PEG chains. This localized modification selectively reduces affinity for regulatory T cells while preserving or enhancing affinity for IL-2Rβγ receptors on killer immune cells, achieving improved selectivity without sacrificing overall binding efficiency.
Solution Approach 2:
The patent optimizes the degree and position of PEGylation to fine-tune the binding parameters of IL-2. By controlling the number, position, and length of PEG chains, the patent achieves a balance between reducing off-target binding to regulatory T cells and maintaining sufficient affinity for therapeutic effect on killer immune cells.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The PEGylated IL-2 achieves sustained drug release and improved selectivity for killer immune cells, increasing CD8+ T cell expression and enhancing anti-tumor activity with reduced adverse reactions.
Implementation Method 1
6 polyethylene glycol (PEG) modifications are added to the IL-2 molecule to form an inactive drug
Implementation Method 2
the PEGylated IL-2 more prone to bind to IL-2Rβγ receptors in killer immune cells
Data Source
Figure 1~2
AI summary
The present invention discloses a method for preparing a PEGylated biomolecule with controllable binding sites, comprising: (1) PEGylating a biomolecule; (2) binding a barrier to at least one binding site in the PEGylated biomolecule; (3) separating the PEGylated biomolecule not bound to the barrier; and (4) separating the barrier and the PEGylated biomolecule bound thereto. In another aspect, the present invention discloses a method for preparing a PEGylated IL-2 with controllable binding sites, comprising: (1) PEGylating to couple a PEG with IL-2; (2) binding the PEGylated IL-2 to an IL-2a receptor; (3) separating the PEGylated IL-2 not bound to the IL-2a receptor; and (4) separating the IL-2a receptor and the PEGylated IL-2 bound thereto. By regulating the binding sites of IL-2, only 1 or 2 PEGs are added during PEGylation.